Adverse effects of trade liberalization, and trade agreements on health are not inevitable. They are the result of how we have managed trade—to enhance profits of the drug companies, not to enhance the health of those in the developing countries. The author proposes that we can reform our trade regimes and the way we finance and encourage research into drugs so as to improve health—and even lower costs.